The NIH Indirect-Cost Cap Just Died in Court. The Grift Is Already Looking for a New Host.

The newsroom coffee tastes like burnt rubber and broken promises. My phone keeps buzzing with the same kind of alert that only hits when power gets caught with its hand in the grant drawer: the government blinked. Not with a press conference. Not with an apology. With a deadline that came and went, quietly, like a lobbyist slipping out of a hearing before the questions start landing.

This week, the Trump administration let the window close to ask the US Supreme Court to revive the NIH’s flat 15% cap on reimbursing universities and medical centers for so-called indirect costs of research. The cap is dead, at least in this lawsuit. And no, the people who tried to impose it are not suddenly going to respect public science. They are just going to look for a new host body.

What happened: the Supreme Court deadline passed

On February 7, 2025, NIH announced it would cap reimbursements for indirect costs at 15%, replacing negotiated rates that commonly run higher. The policy got sued immediately. A federal appeals court later upheld a permanent block, finding NIH’s move unlawful, including because of a long-running appropriations rider and because NIH ran roughshod over HHS regulations that require negotiated rates to be accepted absent a proper deviation process. Then the administration simply did not file a Supreme Court petition before the deadline. Door closed.

Translation: “indirect costs” are the lights, the locks, and the people

Translation: “Indirect costs” is the phrase that lets politicians cosplay as accountants while they set fire to the infrastructure that makes research possible.

These dollars pay for electricity that keeps freezers from thawing. Compliance staff that protects human subjects. Techs who keep instruments calibrated. Cybersecurity that keeps patient data from being sold like loose cigarettes. Calling it “overhead” is like calling brakes “optional accessories.”

And the government’s own brag sheet tells you the size of the cut. The First Circuit opinion notes NIH publicly touted more than $4 billion a year in “savings” from the cap. That is not trimming fat. That is a planned amputation.

Here is the mechanism: sabotage the commons, then sell the cure

Here is the mechanism: you kneecap the public pipeline, then point at the wobbling and call it “inefficient.” Then you invite private capital to “modernize” what you just damaged on purpose.

If you cap indirects, you do not just hurt Harvard. You hit state university medical centers, regional cancer centers running trials, and public health labs that sequence outbreaks. You squeeze graduate students and postdocs who already keep the engine running while being paid like a rounding error.

Follow the money: costs shift down, control shifts up

Follow the money: the cap would have shifted costs off the federal ledger and onto institutions, workers, students, and patients. That turns federally funded science into an unfunded mandate. When budgets blow up, you get hiring freezes, delayed maintenance, and soft privatization.

And the retreat now? No “we were wrong.” Just silence. C&EN reports the White House and DOJ did not respond to requests for comment. Silence is a strategy when you want the heat to die down but the agenda to survive.

The quiet part: it was also a loyalty test

The quiet part: when funding can be yanked by administrative fiat, institutions start self-censoring. They pick “safer” topics. They learn the new rules without anyone writing them down.

Today, the cap is blocked. Good. Take the win like a receipt, not a bedtime story. Demand oversight, audits, and hearings where officials explain who drafted the cap, who lobbied for it, and what pressure got applied. Because if they cannot kill research by cap, they will try it by conditions, gag rules, and budget starvation.